Bajaj HealthCare (BAJAJHCARE) Stock Overview
A pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
BAJAJHCARE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bajaj HealthCare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹410.15 |
| 52 Week High | ₹745.00 |
| 52 Week Low | ₹399.45 |
| Beta | 0.29 |
| 1 Month Change | -8.30% |
| 3 Month Change | -5.89% |
| 1 Year Change | -13.97% |
| 3 Year Change | -4.66% |
| 5 Year Change | n/a |
| Change since IPO | 13.00% |
Recent News & Updates
Recent updates
It's Unlikely That Bajaj HealthCare Limited's (NSE:BAJAJHCARE) CEO Will See A Huge Pay Rise This Year
Sep 20
What Bajaj HealthCare Limited's (NSE:BAJAJHCARE) P/S Is Not Telling You
Jul 03Bajaj HealthCare's (NSE:BAJAJHCARE) Promising Earnings May Rest On Soft Foundations
Jun 02Here's Why Bajaj HealthCare (NSE:BAJAJHCARE) Has A Meaningful Debt Burden
Jan 22Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Rockets 46% As Investors Are Less Pessimistic Than Expected
Dec 19Estimating The Intrinsic Value Of Bajaj HealthCare Limited (NSE:BAJAJHCARE)
Dec 10Bajaj HealthCare's (NSE:BAJAJHCARE) Dividend Will Be ₹1.00
Sep 12Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Jul 12Bajaj HealthCare (NSE:BAJAJHCARE) Has Announced That Its Dividend Will Be Reduced To ₹1.00
Sep 10We Think That There Are More Issues For Bajaj HealthCare (NSE:BAJAJHCARE) Than Just Sluggish Earnings
Nov 19Bajaj HealthCare Limited (NSE:BAJAJHCARE) Soars 30% But It's A Story Of Risk Vs Reward
Jan 17Shareholder Returns
| BAJAJHCARE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.9% | 0.6% | 1.2% |
| 1Y | -14.0% | -3.0% | -2.4% |
Return vs Industry: BAJAJHCARE underperformed the Indian Pharmaceuticals industry which returned -2.2% over the past year.
Return vs Market: BAJAJHCARE underperformed the Indian Market which returned -2.3% over the past year.
Price Volatility
| BAJAJHCARE volatility | |
|---|---|
| BAJAJHCARE Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.6% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: BAJAJHCARE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: BAJAJHCARE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 918 | Sajankumar Bajaj | www.bajajhealth.com |
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 – amino – 1 – adamantanol, N – boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide).
Bajaj HealthCare Limited Fundamentals Summary
| BAJAJHCARE fundamental statistics | |
|---|---|
| Market cap | ₹12.97b |
| Earnings (TTM) | ₹511.81m |
| Revenue (TTM) | ₹5.74b |
Is BAJAJHCARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAJAJHCARE income statement (TTM) | |
|---|---|
| Revenue | ₹5.74b |
| Cost of Revenue | ₹3.17b |
| Gross Profit | ₹2.57b |
| Other Expenses | ₹2.05b |
| Earnings | ₹511.81m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.21 |
| Gross Margin | 44.71% |
| Net Profit Margin | 8.92% |
| Debt/Equity Ratio | 45.5% |
How did BAJAJHCARE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 01:04 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bajaj HealthCare Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.